- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioInvent International AB (BINV)
The BioInvent International share price today is 25.800, view ST BINV stock exchange data. Track the latest BioInvent International share price with real-time updates on BINV stock performance including market cap, day range, 52-week range and dividend yield. Access BINV charts, earnings dates and analyst estimates to support your investment decisions.
Stockholm
Currency in SEK
25.800
+0.300(+1.18%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.750
25.800
52 wk Range
19.220
41.600
BINV is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.75025.800
52 wk Range
19.22041.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BINV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
95.000
Upside
+268.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 95.000
(+268.22% Upside)
Earnings
Latest Release
29-04-2026
EPS / Forecast
-1.90 / -1.90
Revenue / Forecast
14.88M / 15M
Compare BINV to Peers and Sector
Metrics to compare | BINV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBINVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.0x | −4.4x | −0.5x | |
PEG Ratio | −0.18 | −0.01 | 0.00 | |
Price/Book | 3.8x | 3.7x | 2.6x | |
Price / LTM Sales | 7.7x | 5.4x | 3.1x | |
Upside (Analyst Target) | 252.9% | 110.1% | 55.1% | |
Fair Value Upside | Unlock | 13.0% | 7.2% | Unlock |
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies.; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the BioInvent International (BINV) Share Price Today?
The BioInvent International share price today is 25.800.
What is the current BioInvent International (BINV) share price and day range?
As of 21-05-2026, the BioInvent International share price is 25.800, with a previous close of 25.500. The share price has ranged from 24.750 to 25.800 today, while the 52-week range spans from 19.220 to 41.600.
What Is the BioInvent International Market Cap?
As of today, BioInvent International market cap is 1.700B.
What Is the BioInvent International (BINV) Share Price Target?
The average 12-month share price target for BioInvent International is 95.000, with a high estimate of 110 and a low estimate of 85. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +268.22% Upside potential.
What Is BioInvent International's Earnings Per Share (TTM)?
The BioInvent International EPS (TTM) is -5.100.
When Is the Next BioInvent International Earnings Date?
BioInvent International will release its next earnings report on 27-08-2026.
From a Technical Analysis Perspective, Is BINV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does BioInvent International Trade On?
BioInvent International is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for BioInvent International?
The stock symbol for BioInvent International is "BINV."
How Many Times Has BioInvent International Stock Split?
BioInvent International has split 8 times.
How Many Employees Does BioInvent International Have?
BioInvent International has 112 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.